Why the study?
Does isradipine reduce 24-hour ambulatory blood pressure in male patients with mild-to-moderate essential hypertension?
Does isradipine reduce 24-hour ambulatory blood pressure in male patients with mild-to-moderate essential hypertension?
Isradipine monotherapy significantly reduces 24-hour ambulatory systolic and diastolic blood pressure in men with mild-to-moderate essential hypertension.
Answers are grounded in this paper and cite their sources.
Supports isradipine monotherapy in mild-to-moderate hypertension; confirms ambulatory efficacy versus placebo in men.
The antihypertensive effect of isradipine compared with placebo was assessed in 28 male patients (aged 40-64 years) with mild-to-moderate essential hypertension. After withdrawal of all previous antihypertensive treatment, these patients were entered into a 4-week placebo period followed by randomization to receive double-blind, for 8 weeks, either placebo (n = 14) or isradipine at 1.25-2.5 mg twice daily (n = 14). Twenty-four-hour ambulatory blood pressure was measured by Accutracker at the end of the placebo period and at the end of active treatment. In the isradipine group, both systolic and diastolic blood pressures decreased significantly (p less than 0.0001) whereas blood pressure increased in those taking placebo. In addition, isradipine as monotherapy controlled blood pressure throughout the day and night, and especially during the early morning, in these patients.
No takes yet. Share an insight, caveat, or question.
Viskoper et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: